Lung Cancer Trial, Recruiting (NCT07652736)

Lung Cancer Trial, Recruiting NCT07652736 Sponsor: BeOne Medicines Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07652736 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

A participant or their legal representative must sign a written consent form agreeing to take part in the study.
People who are already receiving a medication called tislelizumab as part of their normal, standard medical care, as decided by their treating doctor, for one of four specific approved conditions.

Note: The treating doctor must have already decided to prescribe tislelizumab before any consideration of the patient joining this study, and that decision must be made completely separately from the study.

Who may not be able to join:

People who are not able to fully understand what taking part in the study involves.
People for whom tislelizumab is considered medically unsuitable, either in their doctor's opinion or based on the official guidelines for the medication.
People who their doctor considers ineligible based on their medical situation or the official guidelines for tislelizumab.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 15 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Study Director, BeOne Medicines

Phone: 1-877-828-5568

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07652736

Sponsor: BeOne Medicines

Phase: Not Applicable

Status: Recruiting

Condition: Lung Cancer

Trial contact: 1-877-828-5568

More information: https://clinicaltrials.gov/study/NCT07652736

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

A participant or their legal representative must sign a written consent form agreeing to take part in the study.
People who are already receiving a medication called tislelizumab as part of their normal, standard medical care, as decided by their treating doctor, for one of four specific approved conditions.

Who may not be able to join:

People who are not able to fully understand what taking part in the study involves.
People for whom tislelizumab is considered medically unsuitable, either in their doctor's opinion or based on the official guidelines for the medication.
People who their doctor considers ineligible based on their medical situation or the official guidelines for tislelizumab.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 15 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

BeOne Medicines

Registry

ClinicalTrials.gov

Start date

5 June 2026

Est. completion

15 November 2027

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

Time from Diagnosis to First Dose; Duration of Treatment; Number of Participants with Dose Modifications; Number of Participants with Treatment Discontinuation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov